Concepedia

Maria Rosario

MR

Statistics

Publications

25

Citations

5.1K

H-Index

20

Active since

2013

Affiliations

Takeda (United States)(Current)

University of California San Diego

Western University

KU Leuven

Icahn School of Medicine at Mount Sinai

Maria Rosario is an author at Takeda (United States) specializing in vedolizumab therapy, inflammatory bowel disease, and inflammatory bowel disease therapy.

ORCID

Publications per year

2013–2022

25

Publications

25

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text

, , +14

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Bruce E. Sands, Brian G. Feagan, Paul Rutgeerts et al. · Gastroenterology · 2014 · 705 citations · Full text

, , +15

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

William J. Sandborn, Filip Baert, Silvio Danese et al. · Gastroenterology · 2019 · 317 citations · Full text

, , +15

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Maria Rosario, Nathanael L. Dirks, Marc R. Gastonguay et al. · Alimentary Pharmacology & Therapeutics · 2015 · 258 citations · Full text

, , +17

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Séverine Vermeire, Geert D’Haens, Filip Baert et al. · Journal of Crohn s and Colitis · 2021 · 170 citations · Full text

, , +13

1–5 of 25